CCL5 and prostate cancer: In prostate cancer (PCa), ERα positivity inhibits CCL5 expression in cancer-associated fibroblasts (CAFs), leading to reduced macrophage infiltration, migration of M2 macrophages, and inhibition of prostate cancer invasion (24).